摘要
目的探讨奥氮平在肿瘤相关性抑郁与焦虑中的疗效及毒副反应。方法将本院2013年4月至2013年7月收治的179例伴肿瘤相关性抑郁、焦虑的患者随机分为对照组(89例)和观察组(90例),对照组采用安慰、鼓励、帮助、同情及换位思考等心理支持治疗,而观察组给予奥氮平(放疗时5mg/d,连用2周,化疗时5mg/d,连用2周,化疗间歇期不服用)。分析两组的治疗完成情况并记录奥氮平使用期间的毒副反应,分别于治疗前、化疗2、4、6个周期后和放疗后采用Zung抑郁自评量表(SDS)和焦虑自评量表(SAS)评价焦虑、抑郁标准分变化及治疗有效率。结果观察组4、6个化疗周期的完成率高于对照组(P<0.05)。观察组化疗中的SAS评分均低于对照组,化疗4、6个周期的SDS评分均低于对照组(P<0.05)。观察组治疗后SAS和SDS治疗有效率均高于对照,差异有统计学意义(P<0.05)。观察组使用奥氮平后的毒副反应为嗜睡、体重增加、头晕、乏力、口干、便秘和外周水肿。结论奥氮平能够改善肿瘤相关性焦虑与抑郁,临床应用方便,毒副作用小,患者可耐受。
Objective To explore the effect of olanzapine in cancer-related depression and anxiety and the adverse reaction. Methods One hundred and seventy-nine patients with cancer-related depression and anxiety from April 2013 to July 2013 were ran-domly assigned into control group（n=89） and observation group（n=90）. The control group was given psychological support therapy including encouragement, help, compassion and empathy. While only the observation group received olanzapine：5mg/day oral during radiotherapy or chemotherapy for two weeks. The treatment completion status and toxic side effects of olanzapine during use were recor-ded. The Zung self-rating depression scale（ SDS） and self-rating anxiety scale（ SAS） were employed to evaluate the status of depression and anxiety before treatment, at 2nd, 4th and 6th cycle during chemotherapy or after radiotherapy. Results The completion rates of chemotherapy at 4th and 6th cycle were higher in observation group versus control group（ P〈0.05） . The SAS scores at 2nd, 4th and 6th cycle and SDS scores at 4th and 6th cycle during chemotherapy of observation group were lower than those of control group （ P〈0.05） . The toxicity of olanzapine includes sleepiness, weight gain, dizziness, fatigue, dry mouth, constipation and peripheral edema. Conclusion Olanzapine can improve cancer-related anxiety and depression with the well-tolerated adverse effects.
出处
《临床肿瘤学杂志》
CAS
2014年第5期435-438,共4页
Chinese Clinical Oncology
关键词
奥氮平
恶性肿瘤
抑郁
焦虑
Olanzapine
Malignant tumor
Depression
Anxiety
